Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Review of 14-Day Prescription Limit Up for Chuikyo Discussion Again
April 18, 2017
- AMED to Launch Portal Site to Promote Use of Biobanks as Part of Effort to Support Genomic Medicine
April 18, 2017
- With Clinical Research Law Enacted, MHLW Eyes New Panel to Discuss Requirements for “Specified Clinical Research”: R&D Division Head
April 17, 2017
- Japan, South Korea to Hold 2nd Joint Regulation Symposium in May
April 17, 2017
- Clinical Research Law Promulgated
April 17, 2017
- MHLW Never Pressured Bayer on Announcement Timing for Xarelto Issue: Official
April 14, 2017
- Tokyo Govt Orders 2 “Cash-and-Carry” Dealers to Suspend Business
April 14, 2017
- Pricing Debate Timeline Updated, with 3 Hearing Sessions Now Planned
April 13, 2017
- CEFP Setting Sights on Drug Pricing, High-Cost Benefit System
April 13, 2017
- Opdivo’s Optimal Use Guidelines for RCC, Hodgkin’s Lymphoma to Take Effect on April 18
April 13, 2017
- Scrutinize Specific Process of Cost-Based Drug Pricing: Chuikyo Subcommittee
April 13, 2017
- Post-Launch Price Correction Floated for Imported Drugs 1st Approved in Japan: Chuikyo
April 13, 2017
- Average Price of Drugs Prescribed to Outpatients Rising Due to Increase in Number of High-Priced Drugs: CEFP Working Group
April 13, 2017
- Rebates, Allowances Come Up in CEFP Social Security Working Group’s Analysis of Current State of Wholesalers
April 13, 2017
- Xarelto Survey Scandal “Very Regrettable”: Shiozaki
April 12, 2017
- CEFP Social Security Working Group Raises Questions on Price Maintenance Premium, Biosimilar Policy
April 12, 2017
- MHLW to Continue Withholding HPV Vaccine Recommendation
April 11, 2017
- 41 New APIs Approved in FY2016 in Japan: PMDA
April 11, 2017
- MHLW Advisory Panel to Review Mundipharma’s Injectable Pralatrexate on April 21
April 11, 2017
- Certified IRBs to Review How Monitoring/Audits Will Be Conducted for “Specified Clinical Research”: Official
April 10, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…